GE HealthCare (GEHC)

• Market cap: $33.4B
• 1 day: -1.34%
• 5 days: 4.82%
• 1 month: 13.12%
• 3 months: -21.01%
• 6 months: -12.16%
• Year to date: -7.07%
• 1 year: -9.54%
• 5 years: 21.40%
• 10 years: 21.40%
• Sector: Healthcare
• Industry: Health Information Services

About: GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).

Employees: 53,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

53% more first-time investments, than exits

New positions opened: 201 | Existing positions closed: 131

25% more repeat investments, than reductions

Existing positions increased: 491 | Existing positions reduced: 393

3% more funds holding

Funds holding: 1,252 [Q3] → 1,291 (+39) [Q4]

2.64% more ownership

Funds ownership: 81.9% [Q3] → 84.54% (+2.64%) [Q4]

7% more call options, than puts

Call options by funds: $338M | Put options by funds: $316M

14% less capital invested

Capital invested by funds: $35B [Q3] → $30.2B (-$4.79B) [Q4]

36% less funds holding in top 10

Funds holding in top 10: 11 [Q3] → 7 (-4) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $73 0% upside
• Avg. target: $83 14% upside
• High target: $89 22% upside

7 analyst ratings

• positive: 5 71%
• neutral: 2 29%
• negative: 0 0%

Morgan Stanley Patrick Wood 53% 1-year accuracy 8 / 15 met price target	7% upside $78	Equal-Weight Maintained	6 May 2025
UBS Graham Doyle 67% 1-year accuracy 2 / 3 met price target	0% upside $73	Neutral Upgraded	5 May 2025
Goldman Sachs David Roman 41% 1-year accuracy 9 / 22 met price target	13% upside $82	Buy Maintained	1 May 2025
Wells Fargo Larry Biegelsen 39% 1-year accuracy 16 / 41 met price target	22% upside $89	Overweight Maintained	1 May 2025
Evercore ISI Group Vijay Kumar 35% 1-year accuracy 15 / 43 met price target	17% upside $85	Outperform Maintained	1 May 2025